Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 45 | 2025 | 157 | 12.670 |
Why?
|
| Infant, Very Low Birth Weight | 37 | 2022 | 153 | 8.710 |
Why?
|
| Intensive Care Units, Neonatal | 39 | 2025 | 172 | 7.350 |
Why?
|
| Breast Feeding | 32 | 2025 | 139 | 6.620 |
Why?
|
| Mothers | 24 | 2025 | 160 | 5.700 |
Why?
|
| Infant, Premature | 41 | 2025 | 186 | 5.290 |
Why?
|
| Infant, Newborn | 64 | 2025 | 537 | 4.660 |
Why?
|
| Enterocolitis, Necrotizing | 14 | 2022 | 36 | 3.060 |
Why?
|
| Lactation | 11 | 2021 | 51 | 2.380 |
Why?
|
| Infant | 27 | 2025 | 483 | 2.300 |
Why?
|
| Infant Nutritional Physiological Phenomena | 15 | 2025 | 64 | 2.250 |
Why?
|
| Milk Banks | 7 | 2020 | 18 | 2.190 |
Why?
|
| Patient Discharge | 9 | 2025 | 147 | 2.100 |
Why?
|
| Gestational Age | 14 | 2025 | 73 | 1.880 |
Why?
|
| Infant, Premature, Diseases | 6 | 2020 | 26 | 1.800 |
Why?
|
| Enteral Nutrition | 6 | 2022 | 60 | 1.700 |
Why?
|
| Female | 55 | 2025 | 12954 | 1.570 |
Why?
|
| Child Development | 6 | 2020 | 67 | 1.440 |
Why?
|
| Humans | 70 | 2025 | 22947 | 1.430 |
Why?
|
| Infant Formula | 4 | 2020 | 18 | 1.340 |
Why?
|
| Intensive Care, Neonatal | 7 | 2020 | 29 | 1.250 |
Why?
|
| Breast Milk Expression | 10 | 2020 | 33 | 1.180 |
Why?
|
| Social Support | 3 | 2019 | 174 | 1.130 |
Why?
|
| Residence Characteristics | 2 | 2019 | 171 | 1.030 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 256 | 0.860 |
Why?
|
| Prospective Studies | 14 | 2021 | 1493 | 0.820 |
Why?
|
| Male | 34 | 2025 | 12458 | 0.820 |
Why?
|
| Retrospective Studies | 15 | 2025 | 2994 | 0.820 |
Why?
|
| Gastroschisis | 2 | 2020 | 4 | 0.800 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2020 | 12 | 0.790 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 71 | 0.790 |
Why?
|
| Health Care Costs | 4 | 2020 | 61 | 0.770 |
Why?
|
| Goals | 3 | 2017 | 33 | 0.750 |
Why?
|
| Pregnancy | 5 | 2025 | 324 | 0.710 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2016 | 15 | 0.700 |
Why?
|
| Vitamin D | 1 | 2021 | 27 | 0.690 |
Why?
|
| Infant, Low Birth Weight | 2 | 2019 | 16 | 0.680 |
Why?
|
| United States | 7 | 2025 | 1765 | 0.670 |
Why?
|
| Neonatology | 1 | 2020 | 3 | 0.660 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 25 | 0.660 |
Why?
|
| Birth Weight | 7 | 2022 | 38 | 0.660 |
Why?
|
| Diet | 3 | 2022 | 178 | 0.630 |
Why?
|
| Adult | 16 | 2025 | 6923 | 0.630 |
Why?
|
| Infant Care | 3 | 2016 | 17 | 0.630 |
Why?
|
| Child of Impaired Parents | 1 | 2019 | 9 | 0.620 |
Why?
|
| Hospitalization | 5 | 2020 | 286 | 0.610 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 47 | 0.600 |
Why?
|
| Oxidative Stress | 2 | 2018 | 81 | 0.580 |
Why?
|
| Anxiety | 1 | 2019 | 143 | 0.580 |
Why?
|
| Aftercare | 1 | 2018 | 22 | 0.580 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2017 | 147 | 0.570 |
Why?
|
| Stress, Psychological | 1 | 2019 | 206 | 0.550 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 71 | 0.540 |
Why?
|
| Nervous System | 1 | 2017 | 9 | 0.540 |
Why?
|
| Maternal Behavior | 1 | 2017 | 10 | 0.530 |
Why?
|
| Pregnancy in Adolescence | 1 | 2017 | 11 | 0.530 |
Why?
|
| Educational Status | 5 | 2019 | 209 | 0.520 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 219 | 0.500 |
Why?
|
| Depression | 1 | 2019 | 368 | 0.500 |
Why?
|
| Quality of Health Care | 1 | 2017 | 93 | 0.490 |
Why?
|
| Sepsis | 2 | 2017 | 76 | 0.490 |
Why?
|
| Quality Improvement | 1 | 2017 | 128 | 0.480 |
Why?
|
| Informed Consent | 1 | 2015 | 21 | 0.470 |
Why?
|
| Bacteria | 1 | 2016 | 61 | 0.470 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 41 | 0.470 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 27 | 0.470 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 124 | 0.420 |
Why?
|
| Decision Making | 1 | 2015 | 176 | 0.420 |
Why?
|
| Premature Birth | 2 | 2025 | 14 | 0.390 |
Why?
|
| Oxygen | 2 | 2003 | 56 | 0.370 |
Why?
|
| Postpartum Period | 3 | 2021 | 21 | 0.360 |
Why?
|
| Tissue Donors | 3 | 2021 | 65 | 0.350 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 760 | 0.330 |
Why?
|
| Sleep | 2 | 2003 | 268 | 0.320 |
Why?
|
| Nutritive Value | 2 | 2020 | 23 | 0.300 |
Why?
|
| Nutritional Status | 2 | 2020 | 51 | 0.300 |
Why?
|
| Infant, Extremely Low Birth Weight | 3 | 2017 | 17 | 0.290 |
Why?
|
| Cohort Studies | 8 | 2022 | 1417 | 0.290 |
Why?
|
| Models, Biological | 2 | 2009 | 303 | 0.280 |
Why?
|
| Child | 6 | 2025 | 1157 | 0.260 |
Why?
|
| Age Factors | 2 | 2020 | 635 | 0.260 |
Why?
|
| Incidence | 7 | 2020 | 624 | 0.260 |
Why?
|
| Child Language | 2 | 2017 | 17 | 0.250 |
Why?
|
| Qualitative Research | 2 | 2017 | 92 | 0.240 |
Why?
|
| Infant, Extremely Premature | 2 | 2022 | 8 | 0.240 |
Why?
|
| Bottle Feeding | 2 | 2016 | 14 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 362 | 0.240 |
Why?
|
| Anthropometry | 1 | 2005 | 29 | 0.240 |
Why?
|
| Young Adult | 6 | 2025 | 1651 | 0.230 |
Why?
|
| Bedding and Linens | 2 | 2003 | 5 | 0.230 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 168 | 0.230 |
Why?
|
| Carbon Dioxide | 2 | 2003 | 17 | 0.230 |
Why?
|
| Absorptiometry, Photon | 1 | 2025 | 86 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1046 | 0.220 |
Why?
|
| Motor Activity | 2 | 2017 | 267 | 0.220 |
Why?
|
| Risk Factors | 4 | 2017 | 1970 | 0.220 |
Why?
|
| Bone Density | 1 | 2025 | 146 | 0.210 |
Why?
|
| Prone Position | 1 | 2003 | 25 | 0.200 |
Why?
|
| Risk | 2 | 2020 | 162 | 0.190 |
Why?
|
| Maternal Age | 2 | 2019 | 13 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 107 | 0.190 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 53 | 0.180 |
Why?
|
| Respiration | 1 | 2001 | 27 | 0.180 |
Why?
|
| Time Factors | 3 | 2018 | 1262 | 0.180 |
Why?
|
| Docosahexaenoic Acids | 1 | 2021 | 7 | 0.170 |
Why?
|
| Arachidonic Acid | 1 | 2021 | 13 | 0.170 |
Why?
|
| Directive Counseling | 2 | 2019 | 10 | 0.170 |
Why?
|
| Dietary Supplements | 1 | 2021 | 53 | 0.170 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 16 | 0.170 |
Why?
|
| Health Expenditures | 1 | 2020 | 15 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 243 | 0.170 |
Why?
|
| Cognition | 2 | 2017 | 948 | 0.160 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 122 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 235 | 0.160 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 30 | 0.160 |
Why?
|
| Intestinal Atresia | 1 | 2020 | 1 | 0.160 |
Why?
|
| Adolescent | 4 | 2025 | 1881 | 0.160 |
Why?
|
| Linear Models | 2 | 2017 | 193 | 0.160 |
Why?
|
| Intestine, Small | 1 | 2020 | 30 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 63 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 137 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 96 | 0.150 |
Why?
|
| Intestinal Mucosa | 2 | 2018 | 157 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 286 | 0.150 |
Why?
|
| Contraception Behavior | 1 | 2019 | 5 | 0.150 |
Why?
|
| Inflammation | 2 | 2018 | 231 | 0.150 |
Why?
|
| Logistic Models | 2 | 2017 | 351 | 0.150 |
Why?
|
| Chicago | 3 | 2016 | 813 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 55 | 0.150 |
Why?
|
| Nutritional Support | 1 | 2018 | 23 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1412 | 0.140 |
Why?
|
| Food, Fortified | 1 | 2018 | 8 | 0.140 |
Why?
|
| F2-Isoprostanes | 1 | 2018 | 6 | 0.140 |
Why?
|
| Cell Death | 1 | 2018 | 34 | 0.140 |
Why?
|
| Length of Stay | 1 | 2020 | 298 | 0.140 |
Why?
|
| Energy Intake | 1 | 2018 | 77 | 0.140 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2017 | 1 | 0.140 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 6 | 0.130 |
Why?
|
| Protective Factors | 1 | 2017 | 20 | 0.130 |
Why?
|
| Anemia | 1 | 2017 | 30 | 0.130 |
Why?
|
| Probiotics | 1 | 2017 | 15 | 0.130 |
Why?
|
| Oligosaccharides | 1 | 2017 | 10 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2017 | 59 | 0.130 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 54 | 0.130 |
Why?
|
| Peer Group | 1 | 2017 | 32 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 29 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2017 | 102 | 0.130 |
Why?
|
| Bacteremia | 1 | 2017 | 98 | 0.130 |
Why?
|
| Return to Work | 1 | 2016 | 38 | 0.130 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 37 | 0.120 |
Why?
|
| Illinois | 1 | 2016 | 221 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 39 | 0.120 |
Why?
|
| Phylogeny | 1 | 2016 | 44 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 35 | 0.120 |
Why?
|
| Cost of Illness | 2 | 2013 | 43 | 0.120 |
Why?
|
| Feces | 1 | 2016 | 80 | 0.120 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2015 | 3 | 0.120 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 13 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2015 | 109 | 0.120 |
Why?
|
| Cost Savings | 1 | 2015 | 29 | 0.110 |
Why?
|
| Retinopathy of Prematurity | 1 | 2014 | 6 | 0.110 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 2 | 0.100 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 3 | 0.100 |
Why?
|
| Postnatal Care | 1 | 2013 | 6 | 0.100 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 5 | 0.100 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Feeding Methods | 1 | 2013 | 5 | 0.100 |
Why?
|
| Propensity Score | 1 | 2013 | 33 | 0.100 |
Why?
|
| Pharmacopoeias as Topic | 1 | 2012 | 5 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 32 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2012 | 22 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2013 | 57 | 0.100 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2003 | 6 | 0.100 |
Why?
|
| Direct Service Costs | 1 | 2012 | 3 | 0.100 |
Why?
|
| Tidal Volume | 2 | 2003 | 9 | 0.100 |
Why?
|
| Pediatrics | 1 | 2012 | 37 | 0.090 |
Why?
|
| Biomarkers | 3 | 2020 | 476 | 0.090 |
Why?
|
| Sudden Infant Death | 2 | 2003 | 36 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2012 | 57 | 0.090 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2011 | 1 | 0.090 |
Why?
|
| Codon, Terminator | 1 | 2011 | 2 | 0.090 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 1 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2020 | 481 | 0.090 |
Why?
|
| Animals | 5 | 2020 | 3295 | 0.080 |
Why?
|
| Fluconazole | 1 | 2010 | 7 | 0.080 |
Why?
|
| Cultured Milk Products | 1 | 2009 | 2 | 0.080 |
Why?
|
| Mycoses | 1 | 2010 | 19 | 0.080 |
Why?
|
| Milk | 1 | 2009 | 11 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2010 | 36 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 26 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 370 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 260 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 439 | 0.070 |
Why?
|
| Ventricular Pressure | 1 | 1996 | 2 | 0.060 |
Why?
|
| Lidocaine | 1 | 1996 | 20 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 27 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 76 | 0.060 |
Why?
|
| Ion Channel Gating | 1 | 1996 | 176 | 0.050 |
Why?
|
| Blood Gas Analysis | 1 | 2003 | 3 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2003 | 6 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2003 | 18 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 25 | 0.050 |
Why?
|
| Face | 1 | 2003 | 21 | 0.050 |
Why?
|
| Polysomnography | 1 | 2003 | 72 | 0.050 |
Why?
|
| Air | 1 | 2001 | 3 | 0.050 |
Why?
|
| Methods | 1 | 2001 | 12 | 0.050 |
Why?
|
| Environment | 1 | 2001 | 36 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 15 | 0.040 |
Why?
|
| Ranibizumab | 1 | 2020 | 1 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2020 | 3 | 0.040 |
Why?
|
| Choroid Diseases | 1 | 2020 | 2 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 2020 | 4 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2020 | 22 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2020 | 10 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 28 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2001 | 32 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 67 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2001 | 66 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 113 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 373 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 378 | 0.040 |
Why?
|
| Intention | 1 | 2019 | 14 | 0.040 |
Why?
|
| Oceania | 1 | 2018 | 2 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 289 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 9 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 9 | 0.040 |
Why?
|
| North America | 1 | 2018 | 32 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 309 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 51 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 17 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 10 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2018 | 43 | 0.040 |
Why?
|
| Weight Gain | 1 | 2018 | 61 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 2941 | 0.040 |
Why?
|
| Income | 1 | 2018 | 63 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 85 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 41 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 165 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 124 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 219 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 567 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 260 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 51 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 8 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 16 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2001 | 811 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 164 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2015 | 102 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 548 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 250 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 67 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 50 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 2013 | 2 | 0.030 |
Why?
|
| Ampicillin | 1 | 2013 | 5 | 0.030 |
Why?
|
| Gentamicins | 1 | 2013 | 22 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2013 | 16 | 0.020 |
Why?
|
| Cardiology | 1 | 2012 | 45 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 120 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 100 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2011 | 1 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 134 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2011 | 69 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 88 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 1250 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 17 | 0.020 |
Why?
|
| Cholestasis | 1 | 2010 | 7 | 0.020 |
Why?
|
| Colostrum | 1 | 2010 | 4 | 0.020 |
Why?
|
| Candidiasis | 1 | 2010 | 23 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 398 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 801 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 730 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1996 | 15 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 1996 | 8 | 0.020 |
Why?
|
| Sodium Channels | 1 | 1996 | 13 | 0.020 |
Why?
|
| Verapamil | 1 | 1996 | 25 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 30 | 0.010 |
Why?
|
| Lymphoma | 1 | 2001 | 35 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 162 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 196 | 0.010 |
Why?
|